Angelini Farmacéutica (Spain)

Angelini started operating in Spain in 1978 through the acquisition of the laboratory Farma Lepori, which already had a long experience in the Spanish pharmaceutical sector both in the production and in the distribution. In July 2008, Farma Lepori changed its name to Angelini Farmacéutica.

Angelini Spain headquarter is located in Barcelona.

Angelini Farmacéutica Spain is structured in three Business Units: Ethical BU, Fertility BU, Consumer Healthcare BU.

The main therapeutic areas in the Ethical Division Unit are: orthopedics, rheumatology, pain, oncology, palliative care, ophthalmology, infectious diseases, central nervous system, gynecology and women’s health.

In the orthopedics and rheumatology, Angelini is the first one in terms of turnover, being leaders in the area of chondroprotection with Condrosulf, an osteoarthritis symptomatic treatment.

In the oncology, pain and palliative care area, Angelini has recently landed with Avaric, fentanyl citrate sublingual tablets indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy.

In ophthalmology, the product portfolio includes Aredsan, a food supplement with a specific formula (omega 3 fatty acids, lutein and zeaxanthin, vitamins and minerals) based in the Areds and Areds2 studies. Lubristil is another of the main brands in the ophthalmology portfolio: artificial tears with hyaluronic acid indicated for the treatment of the dry eye disease. On the eyelid care are, Estila is already a consolidated brand.

In the neuropsychiatric field, we find Deprax (Trazodone), an anti-depressive, developed by Angelini worldwide in the early 60’s.

Angelini has recently launched Xydalba (dalbavancin), introducing itself in this way in the infectious disease field. Dalbavancin is the first and only IV antibiotic approved for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI), with a single dose regimen of 1500 mg administered over 30 minutes.

In the women’s health area, Angelini Farmacéutica is present with Rosalgin (benzydamine), a vulvovaginal anti-inflammatory product.

We are leaders in the probiotics and breastfeeding field with Lactanza Hereditum. It is the first available probiotic (Lactobacillus fermentum Lc40) in the market, isolated from breastmilk and able to restore the equilibrium in the mammary flora of women during breastfeeding.  

The Fertility BU markets two human derived gonadotrophins, Fostipur and Meriofert Kit, involved in the induction of ovarian hyperstimulation to patients undergoing an Assisted Reproduction Cycle. The other hormone present in the portfolio is Prolutex, a novel subcutaneous progesterone for the Luteal Phase Support.

Consumer Healthcare in Spain is an Angelini’s strategic business unit. The main Consumer Healthcare brands are: Juanola (in the respiratory tract area as cough&cold, sore throat, decongestants...), Leotron (in the Vitamins&Minerals territory), Tantum Verde (benzydamine, an anti-inflammatory for the mouth and throat), and Natura Essenziale (with a broad range of brands and products in the Pharmacy-Natural territory). Other CHC brands are Amukina, Verolax, Secrepat, Tantum and Lubristil Fresh.

MAIN BRANDS THERAPEUTIC AREA
Condrosulf Orthopedics/Rheumatology
Avaric Oncology/Pain/Paliative care
Aredsan, Lubristil, Estila Ophtalmology
Deprax, Acutil Epa CNS
Fostipur, Meriofert Kit, Prolutex Fertility
Rosalgin, Lactanza, Gravidanza, Inofolic Gynaecology
Xydalba Infectious Diseases
Tantum Verde Mouth and throat
Juanola Respiratory tract
Leotron Vitamins & Minerals
Natura Essenziale Pharmacy - Natural care

According to IMS, in the OTC market Angelini Spain holds the 10th position, and the 63rd position in the prescription market (IMS Health Values MAT march 2018).

Angelini Spain employs 206 people, of which 150 are sales representatives spread all over the country.

All Angelini's activities in Spain, both in the consumer healthcare and in the ethical division, produce a turnover of 75 M€ (2017).